Evidence map›Paper›PMID 39910900›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Long-Term Diabetic Retinopathy Treatment Using Silicon Nanoneedles.

Van Phuc Nguyen, Jinheon Jeong, Mi Zheng, Junsang Lee, Josh Zhe, Zhuying Wei, Chi Hwan Lee, Yannis M Paulus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Van Phuc NguyenDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, 21287, USA.ORCID 0000-0001-7466-1483
Jinheon JeongWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Mi ZhengDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, 21287, USA.
Junsang LeeWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Josh ZheDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, 48105, USA.
Zhuying WeiCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan, Ann Arbor, MI, 48109, USA.
Chi Hwan LeeWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Yannis M PaulusDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, 21287, USA.ORCID 0000-0002-0615-628X

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI JEFFREY MUMM · 1985 to 2026
$22.1M
Multimodal Molecular Imaging of Choroidal NeovascularizationR01EY034325 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yannis Mantas Paulus, XUEDING WANG · 2023 to 2026
$2.5M
Development of Nanoneedle Array for Painless and Long-Term Sustained Intraocular Drug DeliveryR01EY033000 · NEI · PURDUE UNIVERSITY · PI LEE, CHI HWAN, PAULUS, YANNIS MANTAS · 2021 to 2025
$1.9M
Real-time In Vivo Visualization of the Molecular Processes in Choroidal NeovascularizationK08EY027458 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAULUS, YANNIS MANTAS · 2018 to 2021
$898k
Alcon Research InstituteFoundation for the National Institutes of Health CHL: R01EY033000International Retinal Research Foundation YMP: FFSGIA16002NEI NIH HHS 1K08EY027458NEI NIH HHS 1R01EY034325NEI NIH HHS K08 EY027458NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY033000NEI NIH HHS R01 EY034325NEI NIH HHS YMP: 1R01EY033000
6 · The paper itself

Abstract

Sustained-release ocular drug delivery systems with minimal invasiveness are critical for managing eye diseases that cause blindness. An innovative platform is presented for painless and long-term sustained ocular drug delivery utilizing controllably biodegradable silicon nanoneedles (Si NNs) conjugated with bevacizumab (Bev) integrated into a tear-soluble subconjunctival patch. The biocompatible patch facilitates easy application in the subconjunctival area of the eye and rapid dissolution in less than one minute upon contact with the tear film in the sclera, eliminating the need for removal procedures. The Si NNs, fabricated with precise control over their degradation kinetics, enable sustained and controlled release of Bev into the ocular tissues. This platform offers enhanced patient comfort, reduced risk of complications, and prolonged therapeutic efficacy. In vivo studies using a rabbit model of retinal neovascularization (RNV), a clinically relevant proliferative diabetic retinopathy (PDR), demonstrate the platform's ability to reduce RNV by 85% over a year, with no observable side effects. These results highlight the potential of this drug delivery method to penetrate the sclera and releaseBev gradually, providing a promising alternative for long-term, controllable ocular therapy. This technology represents a significant advancement in painless, convenient, and effective treatment for eye diseases requiring sustained drug delivery.

Indexed as

Diabetic RetinopathySiliconAnimalsBevacizumabDrug Delivery SystemsRabbitsBevacizumabSiliconanti‐VEGFbiodegradable silicon nanoneedlesdiabetic retinopathy (DR)optical coherence tomography (OCT)photoacoustic microscopyretinal diseasessubconjunctival patch

Identifiers

PMID39910900
PMCPMC11879252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.